Current Health News: Major Developments in Drug Trials, Bird Flu, and Market Movements
Major health sector news includes GSK and Spero stopping a UTI drug trial due to early success, Brazil's bird flu cases and investigations, and the US FDA's approval of Alcon's new dry-eye drug. Additionally, Omada Health seeks a $1.1 billion valuation, while the Missouri Supreme Court reinstates an abortion ban.
GSK and Spero Therapeutics have ceased a late-stage trial for a UTI drug after it met its main goal early, causing Spero's shares to surge. Meanwhile, Brazil is investigating potential bird flu outbreaks, and Alcon has gained FDA approval for a dry-eye treatment.
Granules India reported a profit drop due to competitive pricing, and iTeos Therapeutics plans to wind down after a cancer trial setback. The Missouri Supreme Court has reinstated a strict abortion ban, impacting women's reproductive rights.
Omada Health eyes a $1.1 billion valuation in its US IPO, signaling potential growth in capital markets. Meanwhile, Brazilian officials confirmed the absence of bird flu in one farm, and Sanofi's meningococcal vaccine received FDA approval for infant use.
(With inputs from agencies.)
- READ MORE ON:
- GSK
- Spero
- UTI drug trial
- Alcon
- FDA
- dry-eye drug
- Omada Health
- IPO
- Missouri abortion ban
- bird flu
ALSO READ
FDA Grants Conditional Approval to Novavax's COVID-19 Vaccine
Dr Reddy's New York Facility Receives FDA Observations
Global Health Pulse: FDA Approvals and International Trade Shifts
Noom Navigates FDA Directives with New Compounded Semaglutide Offerings
Novavax COVID-19 Vaccine Gets Limited FDA Approval Amid Skepticism
Google News